Canine Osteosarcoma Cells Exhibit Resistance to Aurora Kinase Inhibitors

Overview

Journal Vet Comp Oncol

Specialties Oncology
Veterinary Medicine

Date 2013 Feb 16

PMID 23410058

Citations 3

Authors

C M Cannon

J Pozniak

M C Scott

D Ito

B H Gorden

A J Graef

J F Modiano

Affiliations

Soon will be listed here.

Abstract

We evaluated the effect of Aurora kinase inhibitors AZD1152 and VX680 on canine osteosarcoma cells. Cytotoxicity was seen in all four cell lines; however, half-maximal inhibitory concentrations were significantly higher than in human leukaemia and canine lymphoma cells. AZD1152 reduced Aurora kinase B phosphorylation, indicating resistance was not because of failure of target recognition. Efflux mediated by ABCB1 and ABCG2 transporters is one known mechanism of resistance against these drugs and verapamil enhanced AZD1152-induced apoptosis; however, these transporters were only expressed by a small percentage of cells in each line and the effects of verapamil were modest, suggesting other mechanisms contribute to resistance. Our results indicate that canine osteosarcoma cells are resistant to Aurora kinase inhibitors and suggest that these compounds are unlikely to be useful as single agents for this disease. Further investigation of these resistance mechanisms and the potential utility of Aurora kinase inhibitors in multi-agent protocols is warranted.

Citing Articles

Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers.

Kim J, Frantz A, Sarver A, Gorden Klukas B, Lewellen M, OBrien T Vet Comp Oncol. 2017; 16(1):E176-E184.

PMID: 29152836 PMC: 5821546. DOI: 10.1111/vco.12368.

The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

Shiomitsu K, Sajo E, Rubin C, Sehgal I Vet Comp Oncol. 2013; 14(1):13-27.

PMID: 23763774 PMC: 3812382. DOI: 10.1111/vco.12046.

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.

Sampson V, Gorlick R, Kamara D, Kolb E Front Oncol. 2013; 3:132.

PMID: 23755370 PMC: 3668267. DOI: 10.3389/fonc.2013.00132.

References

Girdler F, Gascoigne K, Eyers P, Hartmuth S, Crafter C, Foote K . Validating Aurora B as an anti-cancer drug target. J Cell Sci. 2006; 119(Pt 17):3664-75. DOI: 10.1242/jcs.03145. View

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S . Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia. 2009; 11(9):934-44. PMC: 2735802. DOI: 10.1593/neo.09664. View

Arlot-Bonnemains Y, Baldini E, Martin B, Delcros J, Toller M, Curcio F . Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer. 2008; 15(2):559-68. DOI: 10.1677/ERC-08-0021. View

Sorrentino R, Libertini S, Pallante P, Troncone G, Palombini L, Bavetsias V . Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab. 2004; 90(2):928-35. DOI: 10.1210/jc.2004-1518. View

Mimeault M, Hauke R, Batra S . Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther. 2007; 83(5):673-91. PMC: 2839198. DOI: 10.1038/sj.clpt.6100296. View

Oke A, Pearce D, Wilkinson R, Crafter C, Odedra R, Cavenagh J . AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009; 69(10):4150-8. PMC: 2684546. DOI: 10.1158/0008-5472.CAN-08-3203. View

Mealey K, Barhoumi R, Rogers K, Kochevar D . Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Lett. 1998; 126(2):187-92. DOI: 10.1016/s0304-3835(98)00004-4. View

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y . AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110(6):2034-40. DOI: 10.1182/blood-2007-02-073700. View

10.

Lin Y, Immaneni A, Merritt W, Mangala L, Kim S, Shahzad M . Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008; 14(17):5437-46. PMC: 2766914. DOI: 10.1158/1078-0432.CCR-07-4922. View

11.

Fu J, Bian M, Jiang Q, Zhang C . Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007; 5(1):1-10. DOI: 10.1158/1541-7786.MCR-06-0208. View

12.

Gamberi G, Benassi M, Bohling T, Ragazzini P, Molendini L, Sollazzo M . C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology. 1998; 55(6):556-63. DOI: 10.1159/000011912. View

13.

Liao A, McCleese J, Kamerling S, Christensen J, London C . A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet Comp Oncol. 2009; 5(3):177-96. DOI: 10.1111/j.1476-5829.2007.00137.x. View

14.

BOGENMANN E, Moghadam H, DeClerck Y, Mock A . c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res. 1987; 47(14):3808-14. View

15.

Pryer N, Lee L, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington J . Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res. 2003; 9(15):5729-34. View

16.

Inoue M, Shiramizu K . Immunohistochemical detection of p53 and c-myc proteins in canine mammary tumours. J Comp Pathol. 1999; 120(2):169-75. DOI: 10.1053/jcpa.1998.0268. View

17.

Gallagher R, Collins S, Trujillo J, McCredie K, AHearn M, Tsai S . Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979; 54(3):713-33. View

18.

Ducat D, Zheng Y . Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004; 301(1):60-7. DOI: 10.1016/j.yexcr.2004.08.016. View

19.

Mendoza S, Konishi T, Dernell W, Withrow S, Miller C . Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res. 1999; 18(6A):4449-53. View

20.

Ernst T, Hochhaus A . Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol. 2012; 39(1):58-66. DOI: 10.1053/j.seminoncol.2011.11.002. View